Analyst Ratings For NASDAQ:DCPH – Deciphera Pharmaceuticals (NASDAQ:DCPH)
Today, B. Riley lowered its price target on NASDAQ:DCPH – Deciphera Pharmaceuticals (NASDAQ:DCPH) to per share.
Some recent analyst ratings include
- 10/23/2017-Nomura initiated coverage with a Buy ➝ Buy rating.
- 10/23/2017-Piper Jaffray initiated coverage with a Overweight ➝ Overweight rating.
- 10/23/2017-Instinet initiated coverage with a Buy rating.
- 10/23/2017-JMP Securities initiated coverage with a Mkt Outperform ➝ Outperform rating.
- 10/23/2017-JPMorgan Chase initiated coverage with a Overweight ➝ Overweight rating.
Recent Insider Trading Activity For NASDAQ:DCPH – Deciphera Pharmaceuticals (NASDAQ:DCPH)
NASDAQ:DCPH – Deciphera Pharmaceuticals (NASDAQ:DCPH) has insider ownership of 20.61% and institutional ownership of 48.19%.
- On 10/2/2017 New Leaf Venture Management Ii, Major Shareholder, bought 375,000 with an average share price of $17.00 per share and the total transaction amounting to $6,375,000.00.
Recent Trading Activity for NASDAQ:DCPH – Deciphera Pharmaceuticals (NASDAQ:DCPH)
Shares of NASDAQ:DCPH – Deciphera Pharmaceuticals closed the previous trading session at 24.94 up +0.27 1.09% with 25.34600067138672 shares trading hands.
